IUD Comparison and Clinical Guidelines

Key Specifications and Efficacy

The American College of Obstetricians and Gynecologists recommends that all five IUDs (Mirena, Liletta, Kyleena, Skyla, and Paragard) are highly effective long-acting reversible contraceptives with failure rates <1% 1, 2
Mirena and Liletta have a failure rate of 0.1% and are FDA-approved for 5 years, though Mirena data support up to 7 years of efficacy 1, 2, 3, 4
Kyleena has a failure rate of 0.1% and is FDA-approved for 5 years 1, 2
Skyla has a failure rate of 0.1% and is FDA-approved for 3 years 1, 2, 3, 4
Paragard has a failure rate of 0.8% and is FDA-approved for 10 years, with data supporting 12 years of efficacy 1, 2, 3, 4

For contraception alone, the American College of Obstetricians and Gynecologists recommends choosing Kyleena (5 years) or Skyla (3 years) for nulliparous women or those preferring a smaller device, and Mirena/Liletta (5 years) or Paragard (10 years) for parous women or those accepting a standard inserter 4
For heavy menstrual bleeding treatment, only Mirena and Liletta are FDA-approved 4
For dysmenorrhea, any levonorgestrel IUD (Mirena, Liletta, Kyleena, Skyla) provides significant symptom improvement, while Paragard may worsen cramping 4

The Centers for Disease Control and Prevention recommends that levonorgestrel IUDs may cause irregular spotting in the first 2-3 months, followed by a progressive reduction in bleeding, with a 20-60% reduction in menstrual blood loss after 3-6 months 7
Paragard may cause unscheduled spotting, light bleeding, heavy or prolonged bleeding in the first 3-6 months, with increased menstrual bleeding potentially continuing indefinitely 5, 6
The American College of Obstetricians and Gynecologists recommends treating bleeding episodes with NSAIDs for 5-7 days, and tranexamic acid for persistent heavy bleeding 5, 6, 7

The American College of Obstetricians and Gynecologists recommends that all IUDs have a small risk of pelvic infection, existing only during the first 21 days after insertion 3, 4
The Centers for Disease Control and Prevention recommends not dismissing new-onset heavy bleeding without evaluation, and ruling out IUD displacement, pregnancy, STIs, or new uterine pathology, especially after the initial 3-6 month adjustment period 5, 6, 7